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Background: Routine single-photon emission computed tomography (SPECT) currently lacks quantitative
information on regional activity concentration (ACC) of the injected tracer (e.g. kBq/ml). Furthermore, little is known
on the skeletal absolute concentration of 99mTc-DPD after intravenous injection in bone scintigraphy. The aim of
this study is to determine ACC in the healthy lumbar vertebrae of patients using a recently published quantitative
SPECT/computed tomography (CT) protocol.
Methods: Lumbar vertebrae ACC estimates were performed in 50 female patients (mean age 69.88 ± 13.73 years)
who had been administered 562.84 ± 102.33 MBq of 99mTc-DPD and had undergone SPECT acquisition 4 h after
the injection. The SPECT/CT system was calibrated against a well counter. Images were reconstructed with Flash3D.
ACC and CT tissue density were measured in volumes of interest drawn over the spongious bone tissue of the
three lower lumbar vertebral bodies when these exhibited no focal CT or SPECT pathology.
Results: Average ACC measured in the normal spongious bone tissue was 48.15 ± 13.66 kBq/ml (95% confidence
interval (CI) 45.81 to 50.50 kBq/ml). This corresponds to a mean standardised uptake value (SUV) of (5.91 ± 1.54)
(95% CI (5.64 to 6.17) SUV). SUV correlated significantly with Hounsfield units (HU) (r = 0.678, p < 0.0001). Significant
negative correlations were observed between age and HU (r = −0.650, p < 0.0001) and between age and SUV
(r = −0.385, p < 0.0001).
Conclusions: The SUVs determined for 99mTc-DPD uptake 4 h post injection are in the same range as those
reported for [18F]fluoride in positron emission tomography. The strong correlation of SUV with bone CT density
underlines the physiological significance of this variable. Our data suggest further investigation of the potential
value of ACC measurement in the diagnosis of pathological conditions such as osteoporosis or in following up
osseous metastases under therapy.
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Quantitative single-photon emission computed tomog-
raphy (QSPECT) was first introduced into nuclear medi-
cine in the 1990s. Rosenthal et al. predicted in 1995 that
estimates of absolute SPECT tracer concentration would
enter the clinical arena in the near future [1]. However, to
date, their prediction has not come true as only few ap-
proaches to QSPECT have been established in clinical
practice (for reviews, see Ritt et al. [2] and Bailey et al. [3]).* Correspondence: michal.cachovan@fau.de
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in any medium, provided the original work is pGilland et al. [4] and Tsui et al. [5,6] have shown that
several physical phenomena have to be taken into ac-
count to achieve absolute quantification in SPECT. One
of the first QSPECT protocols validated in humans was
reported by Willowson et al. [7] who quantified the con-
centration of 99mTc in the cardiac cavity of patients stud-
ied by radionuclide ventriculography. Also our research
group [8] proposed a QSPECT protocol to quantify the
tissue concentration of 99mTc. Our methodology, as well
as that by Willowson et al., involves the use of co-
registered data from X-ray computed tomography (CT)
to correct for attenuation and a window subtraction ap-
proach (dual energy window) to correct for scattered
counts.is an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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predict a strong research interest in quantitative SPECT
in the near future and suggest quantitative bone 99mTc
scanning to be one of the potential fields of clinical
interest. However, little is known on the accumulation of
bone-seeking SPECT radiopharmaceuticals in the skel-
eton in absolute terms. Before the advent of hybrid im-
aging combining SPECT with CT, Israel et al. [9] used
an empirical method to quantify osseous concentration
of 99mTc-methylene diphosphonate (MDP). Their ap-
proach did not include corrections for attenuation. There-
fore, the standard deviations in their results of lumbar
tracer concentration amounting 30% to 40% of the mean
were inevitable, motivating further research in that field.
Building on the methodological set-up developed by Zeintl
et al. [8], we measure in this study the activity concentration
(ACC) of 99mTc-diphosphono-propanedicarboxylic acid (DPD)
in the spongious bone tissue without focal SPECT and
CT abnormalities in women referred for bone scintig-
raphy. Furthermore, we correlate tracer concentration
with bone density and age. Due to the dependence of
Hounsfield units (HU) on various factors including pa-
tient shape and size [10], we also compute and collect
linear attenuation coefficients (LAC) [11] and investi-
gate their correlation with ACC.
Methods
In order to obtain quantitative results, multiple calibra-
tions were necessary. Calibrations were performed using
a protocol proposed by Zeintl et al. [8]. We adopt and
cite the proposed methods in the following description.
Patients
In vivo patient data analysis was carried out with permis-
sion from the Ethical Committee of the University of
Erlangen-Nuremberg. We acquired data for a group of
50 female patients (mean age 69.88 ± 13.73 years; mini-
mum 25 years, maximum 97 years) undergoing 99mTc-
DPD bone scintigraphy of the lumbar region between
February and August 2012 using a standard SPECT/CT
protocol as described in the study of Zeintl et al. [8].
The injected activity of 99mTc ranged from 5.60 to 10.30
MBq/kg (mean 8.26 ± 1.41 MBq/kg) corresponding to
151 to 278 μCi/kg (mean 223 ± 38 μCi/kg). The mean
total activity administered was equal to 562.84 ± 102.33
MBq (15.21 ± 2.77 mCi). SPECT/CT was performed 4 h
after intravenous injection.
The patients in our group were included based on the
following criteria:
 Start of SPECT acquisition within an interval of
4 h ± 30 min post injection
 Access to data on measured injection activity, time
of measurement, time of injection, residual activitymeasurement and time of residual activity
measurement
 Access to patient's weight and height information
 At least one vertebral body of the lumbar vertebrae
(LV 3, 4 and 5) in the field of view (FOV) of both
SPECT and CT acquisitions
 Absence of any kind of metal or surgical implants in
the LV FOV
Based on patient records, there are two main groups
of patients: those studied for work up of back pain (22)
and those examined for staging malignancy (28). In 22
cases of the latter, the primary malignancy had been di-
agnosed in the breast. One woman was diagnosed with
both breast and ovarian cancer. There was one case in-
volving each of the following carcinomas: ovarian,
oesophageal, renal cell and Ewing's sarcoma and osteoid
osteoma.
All three LVs in the 45 patients examined and only
two LVs in the 5 patients examined were in the FOV.
Overall, 145 LVs were considered in this study.
Data acquisition and reconstruction
We used both Symbia T6 and Symbia T2 (CT with a max-
imum of six and two slice acquisitions per rotation, re-
spectively, Siemens Healthcare, Molecular Imaging,
Hoffman Estates, IL, USA) system at the Nuclear Medi-
cine Clinic in Erlangen, Germany to acquire in vivo pa-
tient data. SPECT scans were acquired using low-energy
high-resolution collimation, a 128 × 128 matrix of 4.8-mm
pixel size and a total of 120 projections over 360° with a
dwell time of 15 s/view. Subsequent to the SPECT acquisi-
tion, a low-dose CT scan was acquired with 130 kV and 30
ref mAs using adaptive dose modulation (CARE Dose 4D
available for both Symbia® T6 and T2; Siemens Healthcare
[12]). The CT data were generated with a 2.5-mm slice
thickness using a smooth reconstruction kernel (B08s,
Siemens Healthcare [8]) and a 1-mm slice thickness using
a medium kernel (B41s, Siemens Healthcare).
SPECT reconstruction was performed using Flash3D
(Siemens Healthcare, Molecular Imaging) [13,14].
Flash3D is an ordered subset expectation maximisation
(OSEM) reconstruction algorithm with depth-dependant
3D (axial and trans-axial) resolution recovery, scatter
correction using scatter window subtraction (dual energy
window approach) and attenuation correction based on
attenuation maps derived from the CT data filtered with
the B08s kernel. The OSEM SPECT reconstruction used
four subsets and eight iterations without post-smoothing,
as suggested by Zeintl et al. [8].
Data analysis
From the 145 vertebral bodies (LV 3 to 5), all vertebrae
exhibiting any focal SPECT or CT pathology in their
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based on the diagnosis defined by an experienced phys-
ician. The rationale for this was the intention to measure
ACC in spongious bone tissue not affected by malig-
nancy, compression fractures, osteochondrosis or facet
disease. Overall, 133 vertebrae were selected for analysis
based on the criterion previously defined. Five LV 5,
three LV 4 and four LV 3 were rejected.
The delineation of the volumes of interest (VOIs) was
performed by an experienced physician using the regular
clinical volumetric analysis tool provided by the camera's
vendor (e.soft, Volumetric Analysis, v 1.1.6.1, Siemens
Healthcare, Molecular Imaging) which reports the statis-
tics for the various measures (HU and counts). The B41s
kernel filtered CT data were used to derive the VOI se-
lection in a volumetric fusion display. Elliptical VOIs
were hand-drawn in the lower three lumbar vertebrae
such that the borders coincided with the vertebral cor-
tical bone shell. The average diameter for the selected
disc was 31.81 ± 2.08 mm. We adjusted the axial size of
the VOI in order to delineate a volume of approximately
2 ml. Figure 1 shows a representative patient's fused data
set in transverse and coronal planes with their respective
VOIs. The mean volume of all the selected VOIs was
2.06 ± 0.14 ml. For comparison, we also selected a VOI
which covered the complete vertebral body, resulting in
an average volume of 10.63 ± 2.20 ml with the same
average diameter in the selected disc. We recorded the
overall reconstructed counts, the mean HU, the mean
LAC and the size of the VOI for later analysis. We cal-
culated absolute activity concentration in accordance
with the work of Israel et al. [9]. First, a calibration of
the SPECT/CT system with a uniform phantom is
performed which provides a volume sensitivity factor
and is specific to the camera type, collimator type andFigure 1 Transverse and coronal images of a patient's SPECT/CT fuse
VOIs selected.the window energy settings used. The patient's
reconstructed values are then normalised with volume
sensitivity, allowing the calculation of ACC. All data
were decay-corrected to the time of injection in order to
control fluctuations at the start time of the acquisition.
The administered activity was corrected for residual ac-
tivity in the syringe. Final values of quantitative tracer
concentrations are thus defined with respect to injection
time. Body weight (BW), lean body weight (LBW) and
body surface area (BSA) computed based on other works
[15,16] were used to study standardised uptake value (SUV)
normalisation variations, namely SUVBW (Equation 1),
SUVLBW (Equation 2) and SUVBSA (Equation 3).
SUVBW ¼ ACC WEIGHTINJECTED ACTIVITY ð1Þ
SUVLBW ¼




SUVBSA ¼ ACC  HEIGHT
0:725 WEIGHT0:425  0:007184
INJECTED ACTIVITY
ð3Þ
We also computed, based on the work of Zeintl et al.
[8], the ACC underestimation for the selected VOIs.
This was accomplished using the emission recovery co-
efficient tables for our particular operation point (VOI
size and acquisition parameters) as defined in the work
of Zeintl et al. [8]. These recovery coefficients were
obtained using simulations of hot spheres of different di-
ameters in hot bath and were validated using real phan-
tom acquisitions.d data sets including the three lower LV. The ellipses depict the
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In the ‘Results’ subsection, we report various quantitative
measures, including bone density expressed in HU and
tracer ACC expressed in kilobecquerel per millilitre
(kBq/ml) and SUV. The data are described by their
mean values, their standard deviations and their 95%
confidence intervals (CI). The correlation of the vari-
ables is analysed using linear regression yielding
Pearson's correlation coefficients. The statistical signifi-
cance of differences in the correlation coefficients was
tested using Fisher's transformation (z and p values). Sig-
nificance was accepted at p < 0.05. Statistical analysis
was performed using MedCalc for Windows, version
11.5.0.0 (MedCalc Software, Mariakerke, Belgium).
Results and discussion
Results
Table 1 shows the statistical summary for the various
measures collected. Mean vertebral VOI ACC for the
patient group was 48.15 ± 13.66 kBq/ml (95% CI, 45.81
to 50.50 kBq/ml) or 5.91 ± 1.54 SUVBW (95% CI, 5.64 to
6.17 SUVBW). The VOI analysis showed a mean CT value
of 106.52 ± 58.00 HU (95% CI, 96.57 to 116.46 HU) and a
mean attenuation coefficient of 0.168 ± 0.007 cm−1
(95% CI, 0.167 to 0.170 cm−1). The mean 99mTc-labelled
tracer uptake percentage was in the range of 8.75 × 10−3 ±
2.23 × 10−3 (95% CI, 8.12 to 9.39 × 10−3) injected dose
(% ID) per millilitre of vertebral spongious bone.
Activity concentration (kBq/ml) correlated signifi-
cantly with HU (r = 0.483, p < 0.0001; 95% CI, 0.341 to
0.604). ACC normalised for body mass and injected ac-
tivity, SUVBW, showed even a stronger correlation (z =
2.41, p < 0.05) with bone density expressed in HU (r =Table 1 Statistical analysis of all variables collected for 50
female patients and 133 vertebral bodies
Variable Mean SD 95% CI
Age (years) 69.88 13.73 65.98 to 73.78
Weight (kg) 69.39 13.38 65.59 to 73.19
Height (cm) 160.72 6.05 159.00 to 162.44
Administered activity (MBq) 562.84 102.33 533.76 to 591.92
Activity per 1 kg BW (MBq/kg) 8.26 1.41 7.86 to 8.66
ACC (kBq/ml) 48.15 13.66 45.81 to 50.50
ACC (SUVBW) 5.91 1.54 5.64 to 6.17
ACC (SUVLBW) 3.89 0.92 3.74 to 4.05
ACC (SUVBSA) 5.93 1.40 5.69 to 6.17
% ID per ml (10−3) 8.75 2.23 8.12 to 9.39
Bone density (HU) 106.52 58.00 96.57 to 116.46
LAC (cm−1) 0.168 0.007 0.167 to 0.170
ACC activity concentration, BW body weight, BSA body surface area,
CI confidence interval, HU Hounsfield units, % ID percentage of injected dose,
LAC linear attenuation coefficient, LBW lean body weight, SD standard
deviation, SUV standardised uptake value.0.678, p < 0.0001; 95% CI, 0.575 to 0.761). SUVLBW and
SUVBSA reported comparable statistically significant cor-
relations (r = 0.648, p < 0.0001 and r = 0.637, p <
0.0001, respectively). Figure 2 shows the correlation plot
with 95% confidence and prediction intervals on an ex-
ample of SUVBW and HU dependence.
The correlation of absolute tracer concentration (kBq/ml)
and age was also significant (r = −0.379, p < 0.0001).
Significant negative correlation was observed between
ACC in SUVBW and age (r = −0.385, p < 0.0001; 95%
CI, −0.521 to −0.229) as well as between bone density
(HU) and age (p = −0.650, p < 0.0001; 95% CI, −0.739
to −0.5408) and LAC and age (p = −0.698, p < 0.0001;
95% CI, −0.776 to −0.599). Figure 3 shows the correl-
ation plot between HU and age. Figure 4 visually de-
scribes the SUVBW vs. age relationship. In the case of
SUVLBW and SUVBSA, the data showed comparable statisti-
cally significant negative correlations with age (r = −0.452,
p < 0.0001 and r = −0.424, p < 0.0001, respectively). Table 2
reports on the correlations between the various measures.
The results collected using the two different VOI se-
lection methods correlated significantly (p < 0.0001).
The coefficient of determination (R2) values for HU,
ACC (kBq/ml) and SUV were 0.95, 0.94 and 0.91, re-
spectively. The mean underestimation of activity in the
selected VOIs was 23.6% ± 1.3%.
Discussion
In contrast to positron emission tomography (PET),
SPECT is, to date, not routinely used for quantifying
ACC in absolute terms in the clinical context. This is
due to the lack of protocols correcting for the factors
confounding ACC measurement by SPECT such as tis-
sue attenuation and scatter. However, with the advent ofFigure 2 Correlation plot between ACC and bone density. ACC
(expressed as SUVBW) is on the vertical axis, and bone density (HU) is
on the horizontal axis. The dark red dashed curves depict the 95%
confidence interval, the green dashed curves are the borders of the
95% prediction interval and the blue line shows the linear regression
line fit.
Figure 3 Correlation plot between bone density and age. Bone
density (HU) is on the vertical axis, and age (years) is on the
horizontal axis. The dark red dashed curves depict the 95%
confidence interval, the green dashed curves are the borders of the
95% prediction interval and the blue line shows the linear regression
line fit.
Table 2 Correlation analyses between the measures of







ACC (kBq/ml) 0.483 −0.379 0.422*
ACC (SUVBW) 0.678 −0.385 0.586
ACC (SUVLBW) 0.648 −0.452 0.570
ACC (SUVBSA) 0.637 −0.424 0.552
HU −0.650 0.960
LAC 0.960 −0.698
ACC activity concentration, BSA body surface area, BW body weight, HU
Hounsfield unit, LAC linear attenuation coefficient, LBW lean body weight, r,
Pearson's correlation coefficient, SUV, standardised uptake value. *Correlation
significance for LAC vs. ACC (kBq/ml) was p < 0.001. All the other correlations
were p < 0.0001.
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routine clinical use, the efforts to develop truly quantita-
tive SPECT have considerably gained in momentum. For
example, Zeintl et al. [17] studied quantitative recovery
of SPECT for various sphere sizes and for increasing the
iteration number. In their subsequent work, they quanti-
fied the ACC of 99mTc-DPD in SPECT/CT images of the
bladder, compared it to ACC determined in urine sam-
ples measured in a well counter cross-calibrated against
the SPECT system used and reported a mean quantita-
tive accuracy of 1.1% ± 8.4% (95% CI, −15.4% to 17.5%)
[8]. Likewise, Willowson et al. [18] studied absolute
ACC for cardiac applications in phantoms using correc-
tions for attenuation and scatter and reported a mean
difference of −1% (range, −7% to 4%) for the calculatedFigure 4 Correlation plot between ACC and age. ACC (expressed
as SUVBW) is on the vertical axis and age (years) is on the horizontal
axis. The dark red dashed curves depict the 95% confidence interval,
the green dashed curves are the borders of the 95 % prediction
interval and the blue line shows the linear regression line fit.tracer activities. In their clinical validation study [7], they
compared tracer activities measured using SPECT in the
cardiac cavity after the injection of 99mTc-labelled eryth-
rocytes with ACC determined in blood samples and
reported a mean error of about 1% (range, −6% to 5%).
Such previous work shows that ACC measurements in
absolute terms are feasible in a clinical setting with regu-
lar SPECT protocols.
Quantitative estimations go hand in hand with system
calibration in the routine. PET systems are calibrated on
a daily basis. For current SPECT routine homogeneity
verifications, quality controls and peaking calibrations
are performed. A regular calibration with a 99mTc-filled
uniform phantom as proposed in the study of Zeintl
et al. [8] would be beneficial for quantitative SPECT to
ensure that system volume sensitivity is stable or needs
adjustments in the computations. In our experience, the
system behaviour is stable over time. The sensitivity can
vary between SPECT systems from different vendors and
for differently sized phantoms as Seret et al. [19] have
shown. They report relatively small error bars (−3.83%,
4.15% and 0.76%) for a NEMA standard phantom with a
SPECT/CT Symbia system similar to those used in this
study.
Building on the protocol developed by Zeintl et al., we
extend their work to determine ACC in spongious bone
tissue in patients referred for skeletal scintigraphy, which
is one of the most common nuclear medical procedures.
We compared the VOI selection using thin layers in the
middle of the vertebral body and with ellipsoids, which
contained most of the spongious bone in the vertebral
body. The high R2 value between the two approaches
shows the validity of the thin-layer VOI selection
approach.
Research aimed at quantifying the uptake of diphosphonates
by the skeleton was conducted in the 1970s and 1980s.
Various groups [20-22] used whole body planar exami-
nations along with blood and urine sampling to
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DPD was reported by Buell et al. to be about 40% [21].
The results from these publications also served as a
basis for the radiation dose report published by Weber
et al. that contains dose calculations for various bone
imaging agents [23].
However, owing to the problems in quantifying ACC
in humans described in this study, data on the regional
ACC in, for example, spongious bone is still scarce.
Israel et al. used an empirical thresholding approach to
quantify the concentration of 99mTc-MDP 2 to 4 h after
injection in vivo on SPECT data sets reconstructed with
filtered back projection without attenuation or scatter
correction and reported a mean concentration percent-
age of about 5 × 10−3 of injected activity per millilitre in
the lumbar spine for normal patients [8]. Israel et al. did
not report the resulting ACC in kilobecquerel per milli-
litre. Based on the reported injected activity ranging
from 740 to 925 MBq, the ACC would be in the range
of 37 to 46.25 kBq/ml. We used 99mTc-DPD SPECT data
which were reconstructed using OSEM with depth-
dependent 3D resolution recovery as well as correction
for attenuation and scatter. We also corrected the
injected activity for the residual activity remaining in the
syringe after the injection (8.11% ± 2.97%), minimising
quantitative errors. In our data, mean tracer uptake as
measured in CT- and SPECT-unremarkable spongious
bone of the lumbar spine was 8.75 ± 2.23 × 10−3 % ID
per ml and 48.15 ± 13.66 kBq/ml. The higher DPD
concentration compared to MDP is consistent with
the properties of these imaging agents reported by
Buell et al. [21].
Zeintl et al. [8,17] simulated the behaviour of SPECT
in spherical lesions using phantoms and defined correc-
tion tables for partial volume (PV). In our study, we
computed the underestimation of the activity based on
their PV correction methodology and obtained a mean
tracer activity underestimation of 23.6% ± 1.3%. The cor-
rection tables were defined for spherical lesions having a
lesion-to-background contrast ratio of 1 to 12 in the
work of Zeintl et al. [8]. In order to compute an AC
underestimation factor, a value interpolation between
the known VOI sizes is necessary. This is not possible
for VOIs of non-spherical shape which behave differ-
ently. We anticipate that the quantitative error in the
vertebral body is smaller due to cross talk from the adja-
cent osseous tissue not only in the axial but also in the
dorsal direction. To prove this assumption, a phantom
simulation study needs to be conducted which is out of
the scope of this paper. Partial volume correction
methods based on phantoms and simulations will clearly
give accurate results for phantoms and a good approxi-
mation for similarly shaped regions with homogeneous
activity distribution in patients, such as for the bladderas shown in the study of Zeintl et al. [8]. In order to cor-
rect for partial volume effects in more complex struc-
tures and lesions, simulation studies adapted to their
shape and size will have to be performed, ideally tailored
to each individual patient. However, this is not feasible
on a routine clinical basis. Different VOI selection, e.g.
data maximum, or thresholding techniques even lead to
a more complex behaviour which can exaggerate noise
and create overshoots common in OSEM as well as
Gibbs artefacts in the reconstructed volume [24].
In PET, ACC measurement is part of the clinical rou-
tine. Frost et al. [25] determined ACC 1 h after intraven-
ous injection of [18F]fluoride to be 5.5 SUV. With our
results, we give more insight to SPECT bone ACC, iden-
tify tracer uptake in female patients 4 h post injection
and report a mean tracer uptake of 5.91 SUV for 99mTc-
DPD in spongious osseous tissue that is of the same
magnitude as for [18F]fluoride uptake in PET 1 h post
injection. Clearly, PET is superior to SPECT in terms of
spatial resolution when today's imaging technology is
considered. Nevertheless, SPECT bears the potential of
technological improvement; furthermore, SPECT has the
advantage of lower costs and, at least at present, better
availability than PET in most countries [26].
The diphosphonates bind to the calcium-rich tissue
and the mineral phase of bone hydroxyapatite [27,28].
Bone density correlates with hydroxyapatite's physical
and structural density in the bones as well as with HU
determined using CT [29]. Our results show, the thus
expected, strong correlation of tracer activity concentra-
tion with bone density expressed in HU (r = 0.678).
Bone density decreases with age, in particular in women
[30,31]. The significant correlation between bone density
in HU and patient age is thus not unexpected. Bone dens-
ity as well as age correlated significantly with normalised
ACC expressed as SUV (r = 0.678 and r = −0.385) as well
as with ACC (kBq/ml) (r = 0.483 and r = −0.379, respect-
ively). The significantly stronger correlation of SUV and
HU (z = 2.41, p < 0.05) compared to ACC (kBq/ml) and
HU can be attributed to the reduction of the dependence
of the correlations tested on administered dose as a
confounding variable in this analysis.
CT measurement of HU is patient-dependent and its
precision varies strongly with patient size and the body
part examined. By incorporating a calibration phantom
in the scanned FOV, quantitative CT (QCT) can correct
for these factors [32]. In our study, we simulated QCT
using attenuation maps generated during SPECT recon-
struction. The results showed highly significant correla-
tions between LAC and SUV (r = 0.586, p < 0.0001) and
suggest further investigation of this type of approach for
bone density measurement.
Our data paved the road towards the usage of ACC
and SUV in clinical routine for diagnostic purposes. One
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these variables to monitor therapy of bone metastases.
More specifically, they could be used as adjunct to the
RECIST criteria which to date have neglected the behav-
iour of bone metastases on CT and magnetic resonance
images for methodological reasons [33].
The significant correlation between ACC and SUV on
the one hand and HU and age on the other suggests the
use of quantitative SPECT to study osteoporosis or other
diseases involving bone metabolism. Nevertheless, QCT
would be expected to be more precise for quantification
of bone loss. QCT, however, does not allow the assess-
ment of dynamic indices of bone metabolism such as
bone turnover. Cook and co-workers studied quantita-
tive [18F]fluoride PET in a dynamic acquisition setting
[34] and could, therefore, also calculate kinetic parame-
ters of skeletal fluoride uptake. Zeintl et al. [35] have
shown that quantitative dynamic SPECT is feasible with
current-generation, commercially available equipment.
SPECT/CT thus harbours the potential for the precise
assessment of diseases affecting bone turnover such as
osteoporosis.
Osseous ACC of 99mTc-DPD reflects bone metabolism
only indirectly as this variable is also influenced by
tracer delivery to the osseous tissue. To allow for the
calculation of the transfer constants describing bone me-
tabolism, a measurement of the time radioactivity con-
centration curves in the arterial blood is necessary,
which was not performed in this study. Furthermore, the
binding of the polyphosphonate used by plasma proteins
would have to be taken into account. The latter point is
also important in view of the differences in plasma pro-
tein binding reported for the different bone-seeking
99mTc-labelled agents [36]. All of these factors may be
influenced by various diseases, e.g. renal insufficiency or
hyperparathyroidism so that their analysis is important
also in the clinical context.
A limitation of this paper is that we investigated DPD
in adult women only. Therefore, the data proffered can
only cautiously be generalised to men or younger sub-
jects. All patients in whom SPECT/CT had been
performed had indeterminate lesions in the lumbar re-
gion on planar scans which in most cases corresponded
to degenerative disease of the spine as to be expected in
the age group studied. The VOIs for measuring ACC
and bone density were, however, only placed in
spongious bone tissue not exhibiting focal SPECT or CT
abnormalities. Therefore, the values reported herein are
not affected by degenerative or malignant diseases.
Conclusions
The SUV values determined by SPECT/CT for DPD up-
take of CT- and SPECT-normal spongious bone are in
the same range as those reported for [18F]fluoridemeasured using PET. The strong correlation of SUV
with bone CT density underlines the physiological sig-
nificance of this variable. Our data suggest the further
investigation of the potential value of ACC measurement
in the diagnosis of pathological conditions such as osteo-
porosis or in the follow-up of osseous metastases under
treatment.
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